Millie Capital Management LLC Continues to Hold Stake in Amgen, Inc. (AMGN)
Millie Capital Management LLC continued to hold its position in shares of Amgen, Inc. (NASDAQ:AMGN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,736 shares of the medical research company’s stock at the close of the 2nd quarter. Millie Capital Management LLC’s holdings in Amgen were worth $299,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Wealthsource Partners LLC bought a new position in Amgen in the 2nd quarter valued at approximately $431,000. Colony Group LLC lifted its stake in Amgen by 19.6% in the 2nd quarter. Colony Group LLC now owns 102,409 shares of the medical research company’s stock valued at $17,638,000 after purchasing an additional 16,760 shares during the last quarter. Keel Point LLC lifted its stake in Amgen by 1.2% in the 2nd quarter. Keel Point LLC now owns 3,509 shares of the medical research company’s stock valued at $604,000 after purchasing an additional 43 shares during the last quarter. National Asset Management Inc. lifted its stake in Amgen by 19.7% in the 2nd quarter. National Asset Management Inc. now owns 5,546 shares of the medical research company’s stock valued at $957,000 after purchasing an additional 911 shares during the last quarter. Finally, Krilogy Financial LLC lifted its stake in Amgen by 51.5% in the 2nd quarter. Krilogy Financial LLC now owns 3,125 shares of the medical research company’s stock valued at $538,000 after purchasing an additional 1,062 shares during the last quarter. Institutional investors and hedge funds own 78.62% of the company’s stock.
In other news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares of the company’s stock, valued at $9,888,326.98. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,575 shares of company stock valued at $1,509,339. 0.19% of the stock is currently owned by corporate insiders.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. During the same period in the prior year, the company posted $3.02 earnings per share. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. sell-side analysts forecast that Amgen, Inc. will post 12.66 EPS for the current fiscal year.
Amgen announced that its board has authorized a stock buyback program on Wednesday, October 25th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 3.00%. Amgen’s dividend payout ratio is 41.63%.
Several equities analysts recently commented on the stock. Oppenheimer set a $205.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday. BMO Capital Markets reissued a “hold” rating and issued a $199.00 price objective on shares of Amgen in a research note on Monday, September 25th. Credit Suisse Group reissued a “neutral” rating and issued a $186.00 price objective (up previously from $177.00) on shares of Amgen in a research note on Friday, September 29th. BidaskClub raised shares of Amgen from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 2nd. Finally, Cann reaffirmed a “buy” rating and set a $205.00 price target on shares of Amgen in a research note on Thursday, November 30th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $190.22.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related stocks with our FREE daily email newsletter.